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Causes of Macular Edema 
 
Macular edema is a common phenomenon in various diseases 
where fluid accumulates in between the retinal cells. Both the 
focal and diffuse as well as the more cystic form are 
characterized by extracellular accumulation of fluid, 
specifically in Henle’s layer and the inner nuclear layer of the 
retina. 
The compartmentalization of the accumulated fluid is likely 
due in part to the relative barrier properties of the inner and 
outer plexiform layers. The fluid originates from the 
intravascular compartment. The classic pattern of cystoid 
macular edema with its petaloid appearance originating from 
the fluorescein leakage of perifoveal capillaries may be seen in 
cases of advanced edema of various origins. These include 
postsurgical cystoid macular edema  as well as cystoid edema 
associated with one of the following conditions: diabetes, 
vascular occlusion, hypertensive retinopathy, epiretinal 
membranes, intraocular tumors (e.g., melanoma, choroidal 
hemangioma), intraocular inflammation (e.g., pars planitis), 
macroaneurysm, retinitis pigmentosa, choroidal 
neovascularization and radiation retinopathy. 
Given the heterogeneous etiology of macular edema its 
effective treatment depends upon a better understanding of its 
pathogenesis. In general, formation of macular edema is related 
to metabolic changes, ischemia, hydrostatic forces, and 
inflammatory and toxic mechanisms that influence the 
formation of macular edema to various degrees in the different 
conditions (Table 1). 
Metabolic alterations have a causal role in diabetic 
maculopathy, but also in inherited diseases such as the 
autosomal dominant form of macular edema or macula edema 
in retinitis pigmentosa. Furthermore, ischemia of the inner or 
outer blood-retinal barrier leads to macular edema. Decreased 
perfusion of the retinal capillaries is seen, e.g., in vein occlusion 
and diabetic retinopathy, whereas ischemia plus decreased 
perfusion of the choroid with associated serous retinal 
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detachment occurs in severe hypertensive retinopathy, in 
eclampsia and in rheumatoid disorders. 
Following retinal vascular occlusion the intravascular pressure 
increases and leads to dysfunction of the blood-retinal barrier. 
Similarly, hydrostatic forces are effective in arterial 
hypertension or in eyes with low intraocular pressure and may 
cause fluid accumulation in the macula. Mechanical traction 
such as in epiretinal membranes or in vitreomacular traction 
syndrome promotes macular edema by physical forces. 
The importance of inflammation in macular edema is discussed 
in more detail below. Inflammation apparently plays a role in 
intermediate uveitis, postoperative cystoid macular edema 
(Irvine-Gass syndrome), diabetic macular edema and various 
forms of choroidal inflammatory diseases including Vogt- 
Koyanagi-Harada syndrome and bird shot 
retinochoroidopathy. 
All prostaglandin-like pharmacological agents, even if applied 
topically, can induce macular edema via a cytokine response 
similar to inflammatory conditions. 
The current therapy for macular edema targets conditions 
where mechanical traction, hydrostatic force, or inflammation 
play a pathogenetic role in the formation of macular edema. 
Unfortunately, even the currently available surgical and 
pharmacological treatments have suboptimal results in many 
cases. 
Therefore, there is an obvious need for the development of a 
more effective and targeted treatment that can be satisfied only 
by the better understanding of the pathophysiology of the 
macular edema formation, which differs according to 
theunderlying disease. 
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Tab 1 Causes of macular edema in relation to the underlying disorders 
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Specificities of Diabetic Macular Edema 
 
Diabetic macular edema is the most common cause of visual 
impairment in patients with diabetes mellitus and affects 
approximately 75,000 new patients in the United States every 
year. The incidence of macular edema significantly increases 
with increasing severity of diabetes in both early-onset and 
late-onset diabetic patients. 
Diabetic macular edema tends to be a chronic disease. Although 
spontaneous recovery is not uncommon, 24% of eyes with 
clinically significant macular edema (CSME) and 33% of eyes 
with center-involving CSME will have a moderate visual loss 
(15 or more letters on the ETDRS chart) within 3 years if 
untreated. 
The Early Treatment Diabetic Retinopathy Study (ETDRS) 
defined DME as retinal thickening or presence of hard exudates 
within one disk diameter of the center of the macula. To 
characterize the severity of macular edema the term “clinically 
significant macular edema” (CSME) is used. 
 
The breakdown of the blood-retinal barrier seems to be the 
most important mechanism that explains the extravasation of 
fluid although changes to the retinal blood flow may play a role. 
The blood-retinal barrier consists of the retinal pigment 
epithelium layer (outer blood-retinal barrier) and the vascular 
endothelium (inner blood-retinal barrier) that prohibit the 
passage of macromolecules and circulating cells from the 
vascular compartment to the extracellular and therefore 
intraretinal space. In general, an increase in passive 
permeability through the endothelium can occur via three 
general mechanisms (Fig. 1): 
 
The initial site of damage that results in the increased vascular 
permeability is controversial to date. Although the impairment 
of the perivascular supporting cells such as pericytes and glial 
cells might play a role, the endothelial cell dysfunction and 
injury seem more likely to be the first pathogenetic step 
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towards the breakdown of the blood-retinal barrier early in the 
course of the disease. In order to dissect the molecular and 
pathophysiologic mechanisms that lead to the accumulation of 
fluid in the macular area, we have chosen diabetic macular 
edema as a model. 
 
 
Fig. 1 Three mechanisms of vascular leakage 
 
Cell-to-Cell Junctions and Vascular Permeability 
 
Fluid homeostasis and endothelial permeability is mostly 
regulated by intercellular junctions in the non-diseased retina. 
Intercellular junctions are complex structures formed by the 
assembly of a transmembranous and cytoplasmic/cytoskeletal 
protein component. At least four different types of endothelial 
junctions have been described: tight junctions, gap junctions, 
adherence junctions and syndesmos. Tight junctions are the 
most apical component of the intercellular cleft. 
Although the molecular structure of tight junctions generally 
appears to be similar in all barrier systems, there are some 
differences between epithelial and endothelial tight junctions, 
and between tight junctions of peripheral and retinal 
endothelial cells [ 1 ]. In contrast to tight junctions in epithelial 
systems, structural and functional characteristics of tight 
junctions in endothelial cells respond promptly to ambient 
factors. It is likely that inflammatory agents increase 
permeability by binding to specific receptors that transduce 
intercellular signals, which in turn cause cytoskeletal 
reorganization and widening of the interendothelial clefts. 
Endothelial junctions also regulate leukocyte extravasation. 
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Once leukocytes have adhered to the endothelium, a 
coordinated opening of interendothelial cell junctions occurs. 
 
 
Cellular Interaction and Vascular Permeability 
 
Leukocytic infiltration of the retinal tissue characterizes many 
inflammatory diseases such as diabetes, pars planitis, and 
choroidal inflammatory diseases. In diabetes, activated 
leukocytes adhere to the retinal vascular endothelium [ 2 ]. 
Increased leukostasis is one of the first histologic changes in 
diabetic retinopathy and occurs prior to any apparent clinical 
pathology. 
Adherent leukocytes play a crucial role in diabetic retinopathy 
by directly inducing endothelial cell death in capillaries  
causing vascular obstruction and vascular leakage. Endothelial 
cell death precedes the formation of acellular capillaries [ 2 ]. 
With time, however, acellular capillaries prevail and become 
widespread. Although the mechanism of this destructive 
process remains elusive, it is clear that the interaction between 
the altered leukocytes and the endothelial cells and the 
subsequent endothelial damage represents a crucial 
pathogenic step. 
 
 
Growth Factors, Vasoactive Factors, and Vascular 
Permeability 
 
The disruption of endothelial integrity leads to retinal ischemia 
and vascular endothelial growth factor (VEGF)-mediated iris 
and retinal neovascularization. VEGF is 50,000 times more 
potent than histamine in causing vascular permeability. 
Previous work has shown that retinal VEGF levels correlate 
with diabetic blood-retinal barrier breakdown in rodents and 
humans.  
Flt1(1–3Ig)Fc, a soluble VEGF receptor, reverses early diabetic 
blood-retinal barrier breakdown and diabetic leukostasis in a 
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dose-dependent manner. Early blood-retinal barrier 
breakdown localizes, in part, to retinal venules and capillaries 
of the superficial inner retinal circulation  and can be 
sufficiently reduced by VEGF inhibition. Although VEGF is only 
one of the cytokines involved in the pathogenesis of the 
vascular leakage, it is likely to be one of the most effective 
therapeutic targets. 
There are several other vasoactive factors and biochemical 
pathways affected by sustained hyperglycemia and known to 
be involved in diabetic macular edema, which are discussed in 
more detail in other chapters. 
High glucose concentration leads to increased diacylglycerol 
(DAG) by two pathways: de novo synthesis and through 
dehydrogenation of phosphatidylcholine (PC). Increased levels 
of DAG-mediated protein kinase C (PKC) occur. Several studies 
have shown that a decrease in retinal blood flow occurs with 
PKC activation. Conversely, inhibition of PKC with LY333531 
(Eli Lilly, Indianapolis, IN) normalized decreased retinal blood 
flow in diabetic rats PKC activation causes vasoconstriction by 
increasing the expression of endothelins (especially 
endothelin-1, ET-1). The expression of endothelins can be 
induced by a variety of growth factors andcytokines including 
thrombin, tumor necrosis factor- (TNF-b ), transforming 
growth factor- (TGF-b ), insulin, and vasoactive substances 
including: angiotensin II, vasopressin, and bradykinin. Heparin 
inhibits endothelins, most likely via inhibition of PKC . 
Furthermore, retinal vascular endothelial cells are very 
sensitive to histamine. Several studies have documented 
increased vascular histamine synthesis in diabetic rats and 
humans. The administration of histamine reduces ZO-1 protein 
expression and thus correlates with vascular permeability. The 
H1 receptor stimulates PKC that has been implicated in 
increased retinal vascular permeability . Interestingly, Aiello 
and coworkers showed that administration of LY333531, a 
PKC- isoform-selective inhibitor, does not significantly 
decrease histamine induced permeability but VEGF-induced 
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permeability. In contrast, administration of non-isoform 
selective PKC inhibitors did significantly suppress 
histamine-induced permeability. Furthermore, in vascular 
endothelial cells, advanced glycation end products (AGE) may 
affect the gene expression of endothelins (ET-1) and modify 
VEGF expression. The AGE-stimulated increased VEGF 
expression is dose and time dependent and additive to hypoxia 
 
 
Endothelial Cell Death and Vascular Permeability 
 
Blood-retinal barrier breakdown is at least in part due to 
endothelial cell damage and apoptosis. The pro-apoptotic 
molecule Fas-ligand (FasL) induces apoptosis in cells that carry 
its receptor Fas (CD 95). There is evidence that FasL is 
expressed on vascular endothelium, where it functions to 
inhibit leukocyte extravasation. The expression of FasL on 
vascular endothelial cells might thus prevent detrimental 
inflammation by inducing apoptosis in leukocytes as they 
attempt to enter the vessel. In fact, during inflammation and 
the ensuing TNF- release, the retinal endothelium upregulates 
several adhesion molecules [ 3 ] that mediate the adherence of 
the leukocytes, but also downregulates FasL, thus allowing the 
leukocyte survival and migration to active sites of 
inflammation and infection. In experimental diabetic 
retinopathy, inhibition of Fas-mediated apoptotic cell death 
reduces vascular leakage. The cumulative endothelial cell death 
during the course of diabetes plays a causal role in the 
pathogenesis of the diabetic vascular leakage and maculopathy. 
 
 
Extracellular Matrix Alterations and Vascular Permeability 
 
Degradation of the extracellular matrix affects endothelial cell 
function at many levels causing endothelial cell lability which is 
required for cellular invasion and proliferation, or influencing 
the cellular resistance and therefore the vascular permeability. 
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The degradation and modulation of the extracellular matrix is 
exerted by matrix metalloproteinases, a family of zinc binding, 
calcium dependent enzymes. Elevation of MMP-9 and MMP-2 
expression has been shown in diabetic neovascular membranes 
[ 4 ], although a direct effect of glucose on MMP-9 expression in 
vascular endothelial cells could not be shown. It is probable 
that MMPs participate at various stages during the course of 
the blood-retinal barrier dysfunction and breakdown. Their 
actions include early changes of the endothelial cell resistance 
with influence on the intercellular junction formation and 
function to active participation in the endothelial and pericyte 
cell death that occurs late in the course of the disease.  
 
 
Transcellular Transport and Vascular Permeability 
 
In addition to all the above, an important factor that is involved 
in the regulation of fluid homeostasis is the active cellular 
transport of nutrients and fluid via pinocytosis. Despite the fact 
that pinocytic transport is critically involved in the 
transepithelial fluid exchange, its role in the pathogenesis of 
increased vascular leakage in diabetes is just emerging. 
However, the molecular factors that are involved in the 
pinocytic fluid transport, how they are influenced fromdisease 
stages and how they contribute to the increased vascular 
permeability are unclear. It is currently known that one of the 
factors involved in the regulation of pinocytic transport is 
VEGF. Vascular endothelial growth factor increases vascular 
permeability not only by disrupting the intercellular tight 
junctions between the retinal endothelial cells but also by 
inducing the formation of fenestrations and vesciculo vacuolar 
organelles. The role of VEGF in the disruption of the pinocytic 
transport that is translated into increased vascular 
permeability in disease states is still controversial [ 5 ] . 
Whereas, in highly permeable blood vessels the number of 
pinocytotic vesicles at the endothelial luminal membrane 
transporting plasma IgG is significantly increased, no 
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fenestrations or vesicles were found in the endothelial cells of 
the VEGF affected eyes when examined by electron microscopy. 
Besides the factors that act in concert with VEGF and are 
discussed above, sustained hyperglycemia increases generation 
of free radicals and nitric oxide, which can further affect 
several metabolic pathways and cause oxidative damage and 
subsequent disorganization of the blood-retinal barrier. 
The knowledge of the basic mechanisms involved in vascular 
leakage is essential for the development of an effective clinical 
treatment. With the growing understanding of the 
pathophysiology of the macular edema, the therapeutic 
thinking is likely to change from a merely symptomatic 
treatment (either surgical or medical) to a treatment that 
targets specifically the causal factors involved in its formation 
(e.g., cytokine or growth factor inhibition). 19.3.1.1.3 
Mechanical Factors Involved in the 
Formation of Macula Edema 
Clinical and anatomic evidence indicates that abnormalities in 
the structure of the vitreoretinal interface may play an 
important role in the pathogenesis of DME [ 6 ]. It was 
suggested that vitreoretinal adhesions in diabetic eyes are 
stronger than the shear forces of traction from vitreous 
shrinkage and this in turn may lead to the development of 
vitreomacular traction and subsequently to macular edema 
[ 7 ]. Nevertheless, the risk of developing diffuse macular 
edema was 3.4-fold lower in a group of eyes with complete 
posterior vitreous attachment or complete vitreoretinal 
separation compared to eyes with vitreomacular adhesion. 
The vitreous humor is a gel-like structure composed mostly of 
water (99%), hyaluronic acid, and collagen. A structural barrier 
between the vitreous cavity and the retina is formed by the 
inner limiting membrane (ILM), which is localized between the 
innermost layer of the retina and the outer boundary of the 
vitreous. The ILM shows typical ultrastructural characteristics 
of a basal lamina, is found in close contact with the foot 
processes of Muller cells, and contains proteins that are 
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typically found in basal laminae such as collagen type IV and 
laminin. 
Striated collagen fibrils of the vitreous cortex insert into the 
inner portion of the ILM, which is also known as the hyaloid 
membrane of the vitreous. Detachment of the posterior hyaloid 
membrane with ageing or pathology results in a condensation 
of the posterior vitreous surface (membrana hyaloidea 
posterior). In youth, there is adhesion between the vitreous 
cortex and the ILM that is stronger than the Muller cells 
themselves and Muller cell foot processes become separated 
from their main cell body and remain connected to the 
posterior aspect of the ILM when this is separated from the 
retinal surface. 
There has been a controversial discussion regarding the 
embryonic origin of the ILM, which can be demonstrated as 
early as 4 weeks after gestation in the human eye. 
Traditionally, the ILM has been considered to be synthesized 
by Muller cells. This concept has been challenged by data 
presented by Sarthy and coworkers, who investigated the 
expression of collagen type IV during development of the 
mouse eye. Because collagen IV is an integral component 
of all basal laminae, the detection of its mRNA can be used to 
identify cellular sources of basal lamina production. By in situ 
hybridization at embryonic day 12, no or sparse mRNA for 
collagen type IV was found in the retina, while strong labeling 
was seen in and around the lens, especially in hyaloid vessels in 
the tunica vasculosa lentis. In contrast, collagen type IV itself 
could be readily detected in the ILM by immunohistochemistry. 
Thus ILM collagen type IV is very likely not produced in the 
retina itself, but rather in the lens and tunica vasculosa lentis. 
From there it is apparently deposited on the inner retinal 
surface to form the ILM. 
In support of this are data by Halfter et al., which show that 
also other ILM proteins such as perlecan, laminin-1, nidogen 
and collagen XVIII are expressed predominantly in lens and 
ciliary body, but are not detected in the retina. Taken to gether, 
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ILM proteins appear to originate largely from lens and ciliary 
body, although a contribution of retinal glial cells in 
ILM synthesis cannot be excluded. Gandorfer et al. describe a 
continuous layer of native vitreous collagen covering the ILM 
and a thickened premacular vitreous in diabetic patients. In 
these patients, peeling of the ILM is difficult, but may be 
rewarding, as peeling is thought to release macular edema by 
improving fluid movement between retina and vitreous. 
While the ILM is probably not directly involved in the 
formation of diabetic macular edema (but removed in surgical 
attempts to treat persistent macular edema), the posterior 
vitreous itself may play the dominant role in the pathogenesis 
of DME [ 8 ]. Sustained hyperglycemia can affect several 
biochemical pathways that can lead to liquefaction and 
destabilization of the vitreous gel [9 , 8 ]. 
Such destabilization of the central vitreous with persistent  
attachment of the vitreous cortex to the retina can also induce 
traction on the macula and contribute to the development of 
macular edema. Sebag and coworkers found that although the 
collagen content in controls and diabetics is the 
same, the major crosslink in vitreous collagen is over twofold 
greater in diabetics than controls. Similarly, the levels of early 
glycation products were threefold higher, and advanced 
glycation end products were 10–20 times more abundant in 
vitreous of diabetics than of controls [ 9 ]. 
In a study by Nasarallah and coworkers, diabetic patients who 
are 60 years of age or older with macular edema had a 
significantly higher prevalence of attached posterior vitreous 
than diabetics without macular edema. Furthermore, naturally 
occurring posterior vitreous detachment due to loosening of 
the vitreoretinal adhesion, liquefaction of vitreous gel, and/or 
gel shrinkage is rare in diabetic patients 50 years of age or 
younger. In diabetic patients, the vitreoretinal adhesion often 
remains strong despite gel liquefaction and shrinkage that 
produces a posterior vitreous detachment. 
Posterior vitreous detachment in younger diabetics results 
from diabetes-related vitreous contraction that simultaneously 
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causes traction on the macula that may lead to macular edema [ 
8 ].  
Diffuse diabetic macula edema has been found in association 
with an attached, thickened, and taut posterior hyaloid. As 
immunocyto chemical staining for cytokeratin (found in retinal 
pigment epithelial cells) and glial fibrillary acidic protein 
(found in astrocytes and Muller cells) demonstrated the 
existence of cells in the premacular posterior hyaloid, there is a 
possible role for cell infiltration in the development or 
maintenance of macular edema. It remains to be elucidated 
whether these cells in the posterior vitreous cause macular 
edema physiologically rather than mechanically through the 
production of cytokines. 
 
The traditional methods of evaluating macular diseases such as 
slit-lamp biomicroscopy and stereo fundus photography are 
relatively insensitive at determining small changes in retinal 
thickness. 
Fluorescein angiography is a standard method used to evaluate 
patients with diabetic macula edema and is sensitive for 
detection of fluid leakage. Fluorescein angiographic findings in 
diabetic macula edema can be categorized into three different 
types of leakage: (1) focal leakage: well-defined focal 
area of leakage from microaneurysms or dilated capillaries; (2) 
diffuse leakage: presence of widespread leakage from ill-
defined sources; and (3) diffuse cystoid leakage: diffuse leakage 
and pooling of dye in the cystic spaces of the macula in the late 
phase of the angiogram.  
The most important information gained from fluorescein 
angiography is, however, whether there is macular ischemia or 
not and thus whether any treatment approach would be 
effective or not. Nevertheless, retinal thickness cannot be 
quantified by angiographic means. 
The problem of most other available diagnostic techniques is 
the lack of sufficient resolution to provide structural images of 
the central retina: The resolution of standard clinical 
ultrasound is limited by the sound wave in ocular tissue to 
Gestione dell’edema maculare diabetico Pag. 14 
 
approximately 150 μm, whereas high-frequency ultrasound 
biomicroscopy offers a resolution of approximately 20–40 μm; 
however, its penetration is limited to the first 4 mm of the 
anterior segment. The resolution of confocal imaging 
techniques including scanning laser ophthalmoscope (SLO) and 
scanning laser tomography (SLT) may be limited by ocular 
aberrations [ 9 ]. 
More recently diagnostic techniques have been developed for 
high-resolution imaging of the retina and detection of the 
retinal thickne. Optical coherence tomography (OCT) is  a non-
invasive technique developed for cross-sectional imaging in 
biological systems. It is based on 
determination of the time-of-flight delay of light from different 
depths of tissue using low-coherence interferometry. OCT uses 
infrared illumination of the fundus to take images and thus is 
more comfortable and well tolerated by patients than more 
invasive techniques such as fluorescein angiography. Up to 
now, several studies have shown that OCT is a useful technique 
for quantitative measurement of retinal thickness in patients 
with diabetes. 
Optical coherence tomography of DME has revealed three basic 
structural changes in the neurosensory retina: retinal swelling, 
cystoid macular edema, and serous retinal detachment. Otani 
and coworkers  found that retinal swelling was the most 
common change in the structure of the retina (88%) [ 10 ]. The 
retinal thickness at the central fovea with DME was 250–1,000 
μm (mean 470•}180 μm), whereas normally the retinal 
thickness is approximately 130 μm [ 10 ]. OCT can be used to 
calculate the standardized change in macular thickness 
(CSMT). As shown by Chan and Duker, CSMT is a highly useful 
method for evaluation and comparison of the different 
therapeutic modalities for DME. Moreover, OCT is a more 
sensitive and specific method for objective evaluation of the 
attachment of vitreous strands to the edges of fovea and 
macula and for measurement of macular thickness. 
Unfortunately, OCT image quality can be affected by media 
opacities, and the reliability of the data depends on the skill of 
Gestione dell’edema maculare diabetico Pag. 15 
 
the OCT operator. Another accurate and very sensitive imaging 
technique for diagnosing and monitoring a large spectrum of 
macular diseases is the retinal thickness analyzer (RTA). RTA 
imaging is based on projecting a thin laser slit beam (green 
helium-neon laser, 40 μW) obliquely onto the retina. The 
backscattered light is analyzed by a fundus camera. Depth 
precision and depth resolution of the RTA are 5–10 μmand 50 
μm, respectively. Because of the small variation. 
 
Therapeutic Approaches to (Diabetic) Macular Edema  
 
In an effort to reduce macular edema, at least with some 
rationale, different approaches have been used and found 
effective in certain conditions. Laser coagulation, 
pharmacological approaches, and surgical measures are most 
frequently used While focal laser treatment is recommended in 
patients with focal macular edema, there is no confirmed 
evidence that grid laser treatment improves diffuse diabetic 
macular edema. 
In contrast to the routine clinical treatment, the use of carbonic 
anhydrase inhibition for macular edema is not based upon 
scientific evidence Intravitreal triamcinolone acetonide is 
gaining attention for the treatment of macular edema not only 
as an additive during surgery or in the treatment of persistent 
macular edema, but also as primary treatment in diffuse 
macular edema. Randomized multicenter studies are ongoing 
VEGF inhibitors are promising for the reduction of vascular 
leakage. Clinical studies using VEGF inhibitors are currently 
being performed with two specific molecules; however, neither 
substance is currently available for clinical use outside clinical 
trials. 
19.3.1.3.1 Laser Treatment 
The exact mechanism of action of laser photocoagulation- 
induced resolution of DME is unknown.  
In short, a laser-induced destruction of oxygen-consuming 
photoreceptors is discussed as well as cell death and scarring 
(involving gliosis and RPE hyperplasia) induced by the 
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temporary rise in tissue temperature after laser 
photocoagulation. Oxygen that normally diffuses fromthe 
choriocapillaries into the outer retina can now diffuse through 
the laser scar to the inner retina, thus relieving inner retinal 
hypoxia. There is contrasting data as to whether an increased 
preretinal oxygen partial pressure is involved and allows for 
microvascular repair in the treated areas.  When studying the 
diameter of retinal arterioles, venules, and their macular 
branches before and after macular laser photocoagulation in 
eyes with DME, the macular arteriolar branches were found to 
be constricted by 20.2% and the venular branches 13.8%. This 
was attributed to an improved retinal oxygenation caused by 
the laser treatment which leads to autoregulatory 
vasoconstriction, improving the diabetic macula edema. 
According to another theory, the beneficial effect of laser 
photocoagulation is due to an enhanced proliferation  of retinal 
pigment epithelial and endothelial cells leading to a repair and 
restoration of the blood retinal barrier. 
 
 Tab. 2 Functional outcome of the eyes with clinically significantmacular edema (CSME) with 
less/more diabetic retinopathy (DR) treated with different techniques of laser photocoagulation 
(LP) in the ETDRS. Follow-up was 5 years 
        
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The RPE cells 
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may respond to the injury in several ways: if the lesion is 
relatively small,  the RPE defect can be filled by cell spreading; 
if the defect is relatively large, the cells can proliferate to 
resurface the area, and the RPE can produce cytokines (e.g., 
TGF- ) that antagonize the permeabilizing effects of VEGF.  
 
Tab. 3 Recently published studies investigating the efficacy of panretinal photocoagulation on 
diabetic diffuse macular edema (table constructed by Dr. A. Lux) 
 
Tab. 4  Published studies investigating the efficacy of grid laser treatment on diabetic diffuse 
macular edema 
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Laser therapy is well established in diabetic retinopathy as well 
as in diseases with peripheral retinal ischemia. The Early 
Treatment Diabetic Retinopathy Study (ETDRS) was designed 
to evaluate the effects of argon laser photocoagulation for 
macular edema in a prospective, randomized, multicenter 
clinical trial. Among the subgroup of eyes with mild to 
moderate non-proliferative diabetic retinopathy with macular 
edema, visual acuity improved in 16%, remained unchanged in 
77%, and worsened in 7%of treated eyes, whereas visual 
acuity improved in 11%, remained unchanged in 73%, and 
worsened in 16% of untreated eyes after 2 years of follow-up. 
After 3 years of follow-up, vision worsened in 12%of treated 
eyes compared to 24%of untreated eyes. Furthermore, the 
ETDRS Reading Center identified and analyzed 350 eyes with 
CSME, which had retinal thickening involving the center of the 
macula. After 1 year of  follow-up, retinal thickening in the 
center of the macula was present in only 35% of eyes assigned 
to immediate photocoagulation compared to 63% of eyes 
assigned to deferred photocoagulation. There was a 
statistically significant benefit of laser photocoagulation in this 
group of eyes (Table 2 ). Nevertheless, a current literature 
review indicates that at least in selected groups, a beneficial 
effect of PRP with respect to macula edema can be identified 
(Table 3 ). The exact relationship between peripheral ischemia 
and macula edema and thus the relevance of peripheral 
panretinal photocoagulation in these patients as a treatment 
for macula edema still remains to be determined. 
The standard guidelines for “focal” laser photocoagulation for 
DME have been provided by the ETDRS [ 11 ]. Direct treatment 
of leaking microaneurysms and “grid” treatment of diffuse 
macular edema or non-perfused thickened retina have been 
suggested for mild and moderate non-proliferative diabetic 
retinopathy (NPDR), and combination scatter laser  
photocoagulation and focal laser photocoagulation  has been 
suggested for DME in selected cases of severe NPDR and in 
eyes with PDR (Tables 2 , 4 ). The risk of severe visual loss (30 
letters with final VA <5/200) was not significantly different 
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between the treatment and control groups in each category of 
retinopathy (mild and advanced retinopathy). The risk of 
moderate visual loss (15 letters), however, was significantly 
lower after the first year of follow-up in eyes assigned to the 
laser treatment in each category (less/more severe 
retinopathy) compared to the group of eyes in the control 
group. At early time points, the risk of moderate visual loss in 
the group of eyes with DME and more severe diabetic 
retinopathy was higher (statistically significant  p<0.01) in the 
treatment group compared with the  eyes in the control group. 
In spite of the fact that the 5-year risk of severe visual loss in 
each category (DME with less/more severe retinopathy) is 
lower in the treated group compared with the control group, 
the rates are very low in all groups. 
There was no indication that the development of severe visual 
loss might be influenced by the timing of focal 
photocoagulation in the eyes with macular edema assigned to 
early scatter photocoagulation.  
 
The most effective strategy for reducing the risk of moderate 
visual loss in eyes with macular edema and less severe 
retinopathy was immediate focal photocoagulation with 
delayed scatter (added only if a more severe retinopathy 
developed), whereas eyes assigned to immediate full scatter 
and delayed focal photocoagulation had an increased risk of 
moderate visual  loss during the first 16months of follow-up 
and thereafter were similar to the eyes assigned to deferral. 
The ETDRS investigators suggested that the reduced rate of 
moderate visual loss is mostly due to the effects of early focal 
photocoagulation, which should be considered for all eyes with 
CSME. Focal photocoagulation has been associated with a lower 
risk of moderate visual loss, an increased chance of visual 
improvement, less loss of color vision, and minor visual field 
changes [ 12 ]. 
Focal burns to microaneurysms surrounding the center of the 
macula should not be larger than 50–100 μm, with a duration 
of 0.05–0.1 s. The preferred endpoint is a whitening or 
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darkening of microaneurysm. Grid pattern (if at all indicated!) 
burns are located above, below, and temporal to the center of 
the macula (spot size: 50–100 μm; duration: 0.05–0.1 s, 
preferred endpoint: mild RPE whitening). Importantly, grid 
treatment is not placed within 500 μm of the center of the 
macula or within 500 μm from the disk margin, but can extend 
up to 2 disk diameters to the macular area. 
Central laser coagulation is definitely not recommended in eyes 
with ischemic maculopathy (Table 19.3.1.6). Although laser 
photocoagulation has been proven beneficial for the treatment 
of DME, it can be associated with several complications such as 
full-thickness retinal break, choroidal neovascularization (Fig. 
3), subretinal fibrosis, or symptomatic scotomata. These 
complications can cause symptomatic visual loss. 
 
  Fig. 3  Complications after grid laser coagulation: a 
enlarged central RPE scars of the left eye, no obvious 
macula edema; b early phase fluorescein angiography 
demonstrates  CNV lesion growing from earlier 
photocoagulation scars of the 
right eye; c late phase with increased leakage of 
fluorescein 
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While focal laser coagulation reduces hypoxic area sand 
directly occludes leaky microaneurysms, the rationale for grid 
laser treatment in diffuse macular  edema is not yet well 
established. Potentially, grid laser may produce its effect by 
thinning the retina, bringing retinal vessels closer to choroidal 
vessels, and permitting the retinal vessels to constrict by 
autoregulation, thereby decreasing retinal blood flow and 
consequently decreasing edema formation. Currently there is 
no confirmed evidence that grid laser treatment improves 
diffuse diabetic macular edema. Olk and coworkers 
demonstrated in a randomized study including 303 eyes that 3 
years after grid laser treatment 14.5%of the treated eyes 
improved by 2 lines or more, 60.9% did not change 
significantly and 24.6%deteriorated by more than 2 lines. The 
results, however, were not compared to a non-treated control 
group [ 13, 14 ]. Data from other studies showed similar 
results. The comparability of the different studies is limiteddue 
to the different criteria of inclusion, exclusion, monitoring and 
treatment. Despite the lack of functional improvement (visual 
acuity) there is a reduction of retinal thickness (anatomical 
edema) after grid laser treatment as shown in several studies [ 
14 ]. In conclusion, the 3-year risk of massive visual loss from 
macular edema without focal laser treatment is about 30%, 
compared to 15% after focal laser treatment. Interestingly, 
scatter (panretinal) laser coagulation was not effective, but 
may be even deleterious in patients with mild diabetic 
retinopathy. 
Prophylactic treatment of a non-significant macular edema is 
not advantageous over no treatment. Prophylactic laser 
coagulation is therefore not justified. Laser coagulation of 
diabetic macular edema should only be considered when the 
edema is clinically significant (CSME) (see above). 19.3.1.3.2 
Medical Treatment 
Medical treatment of macular edema so far is best established 
in postsurgical and predominantly inflammatory edema, e.g., in 
uveitis, but is gaining importance in the treatment of diabetic 
macular edema. 
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Therapeutic Approaches to (Diabetic) Macular Edema 
 
The majority of therapeutic strategies inhibit the release of 
inflammatory mediators and therefore target the pathogenetic 
factors responsible for the altered vascular permeability. The 
remaining treatments are mostly symptomatic and include 
carbonic anhydrase inhibitors and methods that increase blood 
flow and oxygenation (e.g., hyperbaric oxygenation, diuresis 
and dialysis, which are so far not applicable for diabetic macula 
edema. 
Medical treatment for diabetic macular edema consists of 
therapeutic agents that are collectively categorized into three 
groups: corticosteroids, cyclooxygenase inhibitors and 
carboanhydrase inhibitors. 
 
Carbonic Anhydrase Inhibitors and Non-steroidal Anti-
inflammatory Drugs 
 
The rationale of carbonic anhydrase inhibitors as a therapeutic 
agent in the treatment of macular edema is to improve the 
ability of the retinal pigment epithelial cells (RPE cells) to 
pump fluid out of the retina. Currently, there are no available 
randomized studies that confirm a beneficial effect of carbonic 
anhydrase inhibitors in the treatment of macular edema. Non-
randomized observations demonstrated improved visual 
function in patients with postsurgical macular edema, e.g., after 
cataract surgery or buckling procedures [ 15 ]. The effect lasts 
only as long as the patient takes the drug (on-off effect, 
tachyphylaxis) [ 15 ]. The favorable reports that were 
described at first regarding the application of carbonic 
anhydrase inhibition in patients with macular edema 
secondary to retinitis pigmentosa are not supported by long-
term observations. With the continuous use of methazolamide 
a rebound phenomenon is observed. In contrast to the routine 
clinical treatment, the use of carbonic anhydrase inhibition for 
macular edema is not based upon scientific evidence to date. 
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The use of carbonic anhydrase inhibitors for diabetic macular 
edema is not recommended. 
As cyclooxygenase inhibitors (NSAIDs) block the synthesis and 
release of prostaglandins, non-steroidal drugs have been 
investigated in the prophylaxis and therapy of postsurgical 
cystoid macular edema. It is clear that NSAIDs target the 
inflammatory mediators that are responsible for the edema 
formation and although they may not be an optimal standalone 
treatment they can be used as steroid-sparing agents. There 
may be several explanations why NSAIDs cannot improve 
vision in diabetic macular edema, such as chronic edema, 
inflammation and ischemia that induce permanent structural 
alterations. Although effects on diabetic vascular leakage were 
achieved in preclinical studies, there is so far no clinical 
evidence for an effect of NSAIDs in diabetic macular edema.  
 
Corticosteroids 
 
Steroids are currently regaining attention with the growing use 
of intravitreal triamcinolone. 
Corticosteroids block the release of arachidonic acid from cell 
membranes and thus reduce the synthesis of prostaglandins. 
Furthermore, they inhibit the migration of leukocytes and the 
release of proinflammatory mediators such as TNF and VEGF. 
Steroids specifically stabilize endothelial tight junctions and 
increase their numbers. As discussed previously, this is 
especially important to the development of macular edema. 
Routes of administration are manifold, including topical, 
periocular, oral, and intravenous routes. 
Subtenon injections of corticosteroids are widely used in 
patients with asymmetric or unilateral uveitis. The advantages 
of the periocular injections are high concentrations of 
corticosteroids in the posterior eye, and reduction of the 
adverse effects compared to systemic administration. 
Intraocular levels of corticosteroids are identical between 
subtenon and retrobulbar administration. For oral 
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administration, the initial high dose (1–1.5 mg/ kg) is 
subsequently decreased according to clinical effect.  
Recent publications suggest that the intravitreal application of 
triamcinolone seems to be a promising therapeutic method for 
macular edema that fails to respond to conventional treatment 
[ 16 ].Martidis et al. published a prospective, non-comparative, 
interventional case series to determine if intravitreal injection 
of triamcinolone acetonide is safe and effective in treating 
diabetic macular edema unresponsive to prior laser 
photocoagulation [16 ]. Sixteen eyes with clinically significant 
diabetic macular edema (CSME) that failed to respond to at 
least two previous sessions of laser photocoagulation were 
included in the study. The response of the laser treatment was 
measured by clinical examination and 
optical coherence tomography (OCT) at least 6months after 
initial laser therapy. Eyes with a residual central macular 
thickness of more than 300 μm (normal: 200 μm) and visual 
loss from baseline were offered intravitreal injection of 4 mg 
triamcinolone acetonide. In this study, the mean improvement 
in visual acuity measured 2.4, 2.4, and 1.3 Snellen lines at the 1, 
3, and 6 month follow-up intervals, respectively. 
The central macular thickness as measured by OCT decreased 
by 55%, 57.5%, and 38%, respectively, over these same 
intervals from an initial pretreatment mean of 540.3 μm 
(•}96.3 μm).  
Intraocular pressure exceeded 21 mmHg in five, three, and one 
eye(s), respectively, during these intervals. One eye exhibited 
cataract progression at 6 months. No other complications were 
noted over a mean follow-up of 6.2 months. Reinjection was 
performed in three of eight eyes after 6 months because of 
recurrence of macular edema. 
Similar pilot studies were performed in patients with uveitis, 
central vein occlusion, and cystoid macular edema after 
cataract surgery [ 17]. In most published reports, complications 
do not appear to be prohibitive; however, all reports 
demonstrate a limited number of selected cases. 
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Further randomized studies are therefore warranted to assess 
long-term efficacy and need for retreatment. Preliminary data 
of Jonas et al. suggests that there is no tachyphylaxis in visual 
acuity or  intraocular pressure outcomes after repeated 
intravitreal injections of triamcinolone acetonide. 
Reviewing the published data on intravitreal injections of 
triamcinolone acetonide, the therapeutic window seems very 
wide. The dose range of intravitreally injected triamcinolone 
acetonide varies from 2 mg [6] to 4 mg [ 17 ] and even 25 mg in 
a single report [ 18 ]. Interestingly, reaccumulation of fluid in 
cystoid spaces occurs between 6 weeks and 3months after 
injection, and this does not seemtobe dose dependent. 
Repeated injections at intervals ranging from 10 weeks to more 
than 6 months show a variable treatment response. There are 
currently no data on the pharmacokinetic 
profile of intravitreal triamcinolone, which might be altered 
froma previous vitrectomy. Physiological intravitreal cortisol 
levels are reported to be 5.1 ng/ml, and vitreous levels after 
peribulb ar injections are in the range of 13mg/ml. The 
effective dose of the triamcinolone acetonide is further 
influenced by the mandatory washes of the widely used 
stabilizing agent benzylethanol during the preparation of the 
injection that even if standardized alter the remaining amounts 
of the drug in the solution. Additionally, an inhibitory effect of 
the stabilizing agent on the drug cannot be excluded. 
Jaffe and coworkers [ 19, 20 ] constructed a fluocinolone 
acetonide drug delivery device that releases  fluocinolone 
acetonide in a linear manner over an extended period. A 
clinical phase III study by Bausch & Lomb investigated the 
efficacy of 0.5 mg (slow release) fluocinolone acetonice in 80 
patients with diffuse diabetic macular edema. Patients 
receiving the implant showed a statistically significant 
regression of retinal thickness after 6 months in comparison 
to the contnol group. Furthermore, 80% of the eyes in the 
treatment group demonstrated a stable or improved visual 
acuity compared to only 50% of the eyes of the control group. 
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Complications of intravitreal triamcinolone acetonide delivery 
systems comprise retinal detachment, vitreous hemorrhage, 
increased intraocular pressure, cataract formation, and 
pseudohypopyon. Elevation of the intraocular pressure after 
triamcinolone acetonide of more than 5 mmHg has been 
reported in up to 30% of eyes. It is therefore prudent that 
patients are asked about any history of a previous steroid 
response. The incidence of culture- positive endophthalmitis 
following intravitreal triamcinolone is as rare as 0.87% in a 
large, multicenter, retrospective case series. It occurs rapidly 
(median 7.5 days) and can result in severe loss of 
vision and the eye. The risk of endophthalmitis is considerably 
higher compared to other intravitreally injected drugs. 
Engstrom and Holland reported the rate of endophthalmitis 
following intravitreal ganciclovir  injection as 0.29% (4 cases in 
1,372 injections). The greater risk of endophthalmitis following 
intravitreal triamcinolone injection may be 
partly due to a small-size bias or an increased susceptibility to 
infections in diabetic individuals. Roth and coworkers reported 
on seven patients who developed a clinical picture simulating 
endophthalmitis following intravitreal triamcinolone injection. 
Extensive signs of inflammation developed 1–2 days after 
injection, at an earlier time point than in bacterial 
endophthalmitis. Vitreous taps were sterile and inflammation 
resolved spontaneously   with recovery to preinjection visual 
acuity or better. This inflammatory response might be a 
response to the stabilizing additive benzylethanol (see above). 
In any case, it is recommended to follow a sterile protocol for 
intravitreal injections of triamcinolone acetonide. 
 
 
 
 
 
 
 
 
Gestione dell’edema maculare diabetico Pag. 27 
 
Tab  6 Recommendations when performing intravitreal triamcinolone acetonide injections. (Modified 
after [122]) 
 
 
 
Antiangiogenic Treatment 
 
VEGF is one of the most potent angiogenic growthfactors to 
date. It is secreted by a variety of normal and cancer cells, 
acting as an endothelial cell mitogen and permeability factor, 
which is why it was originally named vascular permeability 
factor (VPF). VEGF antagonists might be effective in diabetic 
macular edema through inhibition of vascular leakage. There 
are currently two products that underwent phase III clinical 
trials in the treatment of neovascular age-related macular 
degeneration: the anti-VEGF pegylated aptamer (pegaptanib, 
Macugen, Eye-Tech Pharmaceuticals – Pfizer) and an anti-VEGF 
humanized neutralizing antibody fragment (ranibizumab, 
Lucentis, Genentech – Novartis). Bevacizumab (Avastin) is the 
full-length antibody that ranibizumab was derived from and is 
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in use for cancer treatment. Currently the off-label use of 
bevacizumab is gaining attention. Nevertheless, unless large 
scale reports with a considerable follow-up are published, such 
offlabel treatment cannot be recommended for broad 
clinical use. So far, all anti-VEGF drugs need to be injected 
intravitreally repetitively.  
There is clinical evidence that traction forces at the 
vitreoretinal interfacemay play an important role in the 
pathogenesis of macular edema. Several authors have studied 
vitrectomy for persistent macular edemaand have suggested 
that release of the tractional forces at the vitreomacular 
interface may improve resolution of the macular edema and 
restore visual acuity (Tables 7, 8 ). The mechanism by which 
the release of traction resolvesmacular edema is only partially 
understood.  
Some investigators hypothesize that vitrectomy may improve 
perifoveal retinal microcirculation. Some hypothesize that the 
posterior hyaloid exerts tangential tractional forces that lead to 
shallow macular detachment and that are released with 
surgery. The observation that patients with a diffuse diabetic 
macula edema have a reduced incidence of posterior vitreous 
detachment generated the idea that posterior vitreous 
detachment during vitrectomy could be used as a 
therapeuticmeasure in patients with macula edema. Hikichi 
and coworkers report a 55%resolution of diabeticmacular 
edema following posterior vitreous detachment. In contrast 
only a 25%resolution of diabeticmacular edema was observed 
in patients with attached hyaloid. Peeling of the inner limiting 
membrane of the retina ensures complete release of tractional 
forces, removes a potential diffusional barrier, and inhibits 
reproliferation of fibrous astrocytes. It is, however, still 
amatter of investigationwhether such mechanical interventions 
effectively resolve macular edema and allow for a long-term 
functional benefit for the patient. 
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Pars Plana Vitrectomy with Posterior Vitreous Detachment 
 
It was demonstrated that a surgically induced posterior 
vitreous detachment in patients with a diffuse diabetic macular 
edema leads to a reduction of macular edema with a 
subsequent increase in visual acuity. 
In the study by Pendergast and coworkers, 27 (49.1%) of 55 
eyes demonstrated improvement in best-corrected visual 
acuity of 2 or more lines. Fiftytwo (94.5%) of the 55 
vitrectomized eyes showed improvement in clinically 
significant macular edema and in 45 eyes (81.8%) the macular 
edema resolved completely during a mean period of 4.5 
months (range 1–13 months). 
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Tab 7 Non-randomized case control studies investigating PPV without ILMpeeling for diabetic 
macular edema. Review of the literature and clinical results 
 
 
Tab 8 Non-randomized case control studies investigating PPV with ILM peeling for diabetic macular 
edema. Review of the literature and clinical results 
 
Eyes with macular ischemia and preoperative best-corrected 
visual acuity of 20/ 200 or less tended to respond less 
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favorably to vitrectomy than eyes lacking these characteristics. 
All eyes had at least 6 months of follow-up after surgery, with 
a mean follow-up of 23.2 months [ 16 ]. 
Lewis et al. and similarly Harbour et al. demonstrated in eyes 
withdiabeticmacula edema and associated macular traction 
that pars plana vitrectomy (PPV) with removal of the posterior 
hyaloid face resulted in reduced macular edema and in 
improved visual acuity. Ikeda and coworkers reported the 
results of PPV with the creation of a posterior 
hyaloid detachment in three eyes with cystoid diabetic macula 
edema. Macular edema resolved in 100% of eyes and was 
associated with an improvement of visual acuity. La Heij et al. 
reported that macular edema resolved in 100% of eyes that 
underwent PPV with induction of a posterior vitreous 
detachment. Postoperatively, visual acuity significantly 
improved. Interestingly, eyes without preoperative macular 
laser photocoagulation had a significantly higher percentage of 
visual improvement than eyes with preoperative macular laser 
treatment. 
Similarly, the report by Otani and Kishi, who studied 13 eyes 
with diffuse or cystoid diabetic macula edema and no posterior 
vitreous detachment, emphasizes the superiority of posterior 
vitreous detachment in these eyes over laser photocoagulation. 
Visual acuity improved in 38% of eyes by more than two lines 
after PPV and removal of the posterior hyaloid, although 
previous laser treatment did not exert any functional benefit 
[21 ]. 
Yamamoto and coworkers retrospectively reviewed records of 
30 eyes with or without posterior vitreous detachment in 
combination with or without epimacular membranes. They 
found an improvement of postoperative function that was 
independent of the preoperative anatomical situation. 
Nevertheless, there are few studies demonstrating a long-term 
follow-up. Micelli-Ferrari and coworkers prospectively studied 
18 eyes with diffuse and cystoid DME that underwent PPV. 
Visual acuity improved significantly 1 month after surgery in 
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the group with diffuse diabetic macula edema, but decreased to 
preoperative values 10 months after surgery. 
Overall most studies demonstrated an improvement of function 
after vitrectomy; however, there was a strong correlation 
between the preoperative and postoperative visual acuity. 
If judging the final benefit, the complications encountered with 
pars plana vitrectomy for diabetic macula edema should be 
considered; these comprise cataract formation (up to 63%), 
retinal detachment (10%), retinal tear (14–21%), tractional 
rhegmatogenous retinal detachment (5–8%), and vitreous 
hemorrhage (12–16%), epiretinal membrane formation  (8–
12%), fibrinoid syndrome (8%), glaucoma (2–8%), 
development of hard exudates (4%), macular ischemia (11%), 
and neovascular glaucoma (4–8%). 
 
 
Vitrectomy and Peeling of the Inner Limiting Membrane 
 
The rationale for vitrectomy (removal of the hyaloid) plus 
peeling of the internal limiting membrane is the postulated 
improvement of fluid diffusion from the retina to the vitreous 
cavity. ILM peeling is the technique of choice for macular holes, 
macular edema, and improved pucker surgery. After pars plana 
vitrectomy, ILM is dissected from the retinal surface. 
Staining with indocyanine green (ICG) or other dyes can be 
used to facilitate visualization with a subsequent peeling of the 
ILM with a microforceps. The ILMcan usually be torn like the 
anterior lens capsule in patients with macular hole, but may be 
more fragile and adhesive in patients with diabetic edema. The 
risks of retinal breaks and consecutive retinal detachment 
(about 5–8%), cataract (up to 63%), and endophthalmitis in 
any vitreous surgery have to be considered (see above). 
However, the foot processes of Muller cells, which adhere to 
the ILM, may be damaged by traumatic peeling of the ILM off 
the retinal surface. Histological studies demonstrated cellular 
elements resembling the plasma membrane of Muller cells and 
other undetermined retinal structures adherent to the retinal 
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side of the ILM [22]. There is an ongoing discussion as to 
whether the use of ICG and the toxicity thereof leads to a more 
traumatic removal of the membrane compared to ILM peeling 
without staining. Arguments for the use of ICG are the better 
control of manipulation and the lower risk of iatrogenic 
damage. In general, with the use of ICG, surgery tends to be 
performed at an earlier stage and with better initial visual 
acuity. Vitrectomy including removal of the ILM aids the 
resolution of diffuse diabetic macular edema and improvement 
of visual acuity and prevents epiretinal membrane formation. 
Gandorfer et al. described 12 eyes with CSME, 11 of which had 
previous laser photocoagulation treatment without 
improvement and that underwent PPV with removal of the 
posterior hyaloid and ILM peeling. Intraoperatively, 10 patients 
had a thickened posterior hyaloid attached to the macula. 
Postoperatively, macular edema completely or partially 
resolved in 10 eyes, and visual acuity improved in 11 eyes. 
The advantage of ILM peeling over vitrectomy alone is the 
complete release of tractional forces and inhibition of 
reproliferation of fibrous astrocytes, which seems to be 
prudent in the eyes of patients with diabetes and advanced 
vitreoretinal interface disease of the macula.  
Our own data suggest that ILM peeling is ineffective in 
resolving the macular edema in CRVO and proliferative diabetic 
retinopathy.  
 
Most  of the presented data for the surgical methods and 
pharmacological treatments represent small case series. In 
order to further evaluate the discussed treatment approaches 
randomized prospective studies in a large population are 
needed. However, not only the endpoint criteria and the 
measurement approaches should be evaluated, but also the 
best time point of treatment or the question of whether to treat 
ischemic forms of macular edema and how. Many studies 
presenting positive treatment results use the anatomical 
reduction of macular edema as their endpoint. It is well known 
that the anatomical endpoint (decrease in retinal thickness, or 
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a “dry macula” on angiography) in many cases differs 
considerably from the functional endpoint (visual acuity 
and reading ability). Grid laser has been shown to be 
efficacious in reducing vascular leakage; however, it does not 
improve visual acuity (see Table 2). Evaluation of trials with 
different protocols remains difficult. Thus, to evaluate the 
efficacy of different treatment approaches a prospective 
randomized design is necessary, which should emphasize 
functional rather than anatomical endpoints. Reading ability is 
an excellent measure of macular function. The measurement 
should include reading acuity, as well as maximum reading 
speed. For this purpose, the standardized Radner Reading 
Charts provide clinically reliable and reproducible results for 
individuals with normal eyesight and for patients with visual 
impairment. These reading test systems, which take into 
account the current international standards for visual acuity 
measurements (EN ISO 8596, NASNRC) and the psychophysical 
requirements for controlling optical item interactions, can 
provide reliable measures for clinical and scientific analyses of 
reading performance. 
Retinal thickness measurement with optical coherence 
tomography (OCT) is an established method for quantitative 
assessment of macular edema. Retinal thickness is determined 
as micrometers maximal thickness within 500 μm around the 
fovea. The normal thickness values for patients without edema 
are as follows: central part of central subfield 155 μm; central 
subfield as a whole 180 μm; inner superior, nasal and inferior 
subfields 260 μm; inner temporal subfield 250 μm; outer 
superior, inferior, and temporal subfields 230 μm; outer nasal 
subfield 250 μm. A desired effect for any treatment is 
decreasing  retina thickness to within normal (175–200 μm). 
A reduction of 75–150 μm from baseline may be shown to be 
clinically significant. It is important to consider the high 
variability in fixation in patients with macular edema. For 
quantitative comparison of retinal thickness in repeated 
measurements during treatment, care should be taken that the 
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system software chooses the point of measurement 
independently of the patient’s fixation. 
The OCT is currently unable to distinguish the ILM from the 
outer retinal layers. However, it might be useful to exclude any 
kind of retinal traction. As discussed above, a large edematous 
cyst might be  clinically difficult to distinguish froma full 
thickness macular hole associated with a macular pucker. OCT 
can easily answer these questions, but does not answer the 
question of ischemia, which in most cases determines whether 
to treat or not. Almost the only indication for fluorescein 
angiography in diabetic patients and patients with macula 
edema is to exclude macular ischemia (Table 5 ). 
Ischemic maculopathy remains untreatable in the area of laser 
coagulation. A foveal avascular zone of more than 500 μm 
should be considered ischemic and thus according to the 
current recommendations cannot be treated. However, there is 
still hope that ischemic maculopathy can be treated 
pharmacologically. For ischemic ophthalmopathy this has been 
demonstrated in a preliminary report using intravitreal 
triamcinolone, which was demonstrated to induce iris 
neovascularization and increase visual function. In contrast it is 
important to note that antiangiogenic drugs such as VEGF 
antagonists potentially increase ischemia and they need to be 
carefully investigated in this respect. 
Early intervention in macular edema is undoubtedly 
advantageous, as the risk of ultrastructural alterations induced 
by a persistent macular edema increases with time. It is well 
known that with time the central avascular zone and the areas 
of ischemia are likely to increase. Late treatment risks 
transitionto untreatable ischemic forms of macular edema. To 
date, how ever, most surgical approaches will only be 
considered for persistent macular edema unresponsive 
to laser treatment or pharmacological approaches.As a general 
rule surgical and medical treatment could be considered for 
eyes with a BCVA 20/50 + 3 (68 ETDRS letters) and 20/320 
(25 ETDRS letters). 
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The different treatment approaches are likely to affect the 
clinical course of macular edema at variable time points and for 
different time periods. While the effect of intravitreal steroids 
is known to deteriorate with time, similar fluctuations are 
likely for other treatments. Especially for the surgical options 
long-term data is currently unavailable. Thus, any treatment 
option should be evaluated for the duration of the anticipated 
beneficial effect and beyond. As macular edema requiring 
treatment appears to be mostly chronic, a follow-up of only 
6–8 weeks is inefficient. 
19.3.1.5 Summary 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
New Therapeutic Strategies: 
Targeting Vascular Endothelial 
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Pegaptanib for Diabetic Macular Edema 
 Factor 
Vision loss associated with diabetes is caused both by retinal 
neovascularization and by damage to the retinal vasculature, 
leading to breakdown in the blood-retinal barrier (BRB) 
and/or ischemia. Diabetic macular edema (DME), a direct 
reflection of this vascular damage, causes a significant 
component of vision loss associated with diabetic retinopathy 
(DR), especially in patients suffering from type 2 diabetes [ 23 ] 
.  Currently, laser photocoagulation is the standard of care in 
treating retinal complications of diabetes, and while it has 
contributed significantly to reducing the incidence of severe 
vision loss, it is basically a destructive intervention that does 
not address the underlying pathophysiology. Indeed, it is 
accompanied by frank destruction of neural tissue and can lead 
to perceptions of nyctalopia, visual field constriction, and 
dyschromatopsia. A progression in the severity of retinopathy 
after treatment is not  uncommon [ 23 ]. There is thus a need 
for newer therapies with fewer side effects, especially 
approaches 
that counter retinopathic change through targeting the 
underlying pathophysiology of DR, rather than relying on ex 
post facto ablation. Tne major area of investigation is the use of 
angiogenesis inhibitors, with vascular endothelial growth 
factor (VEGF) a principal target for inhibition. Over the past 15 
years, an extensive body of research has established that VEGF 
is a key regulator of both physiological and pathological 
angiogenesis, playing a variety of roles in promoting blood 
vessel growth and vascular permeability (see Callout 1). 
Alternative splicing of the human gene yields at least six 
biologically active isoforms, composed of 121, 145, 165, 183, 
189, and 206 amino acids, with VEGF165, the most abundant  
isoform, being principally responsible for diabetes associated 
ocular pathology.  
It is important to note, however, that the family of VEGF 
isoforms is much more than a promoter of angiogenesis as it 
acts in a wide variety of cellular processes (see Callout 2). 
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Accordingly, strategies targeting VEGF in the clinical arena 
must pay particular heed to the potential for adverse events 
when inhibiting all isoforms of VEGF. In this regard, 
systemically administered VEGF inhibitors have been 
associated with an increased incidence 
of hypertension, proteinuria, bleeding and thromboembolic 
events [24]. 
VEGF and Diabetic Retinopathy 
The pathophysiology of DR is complex, with the products of 
several biochemical pathways being potential mediators in the 
relationship between hyperglycemia and retinal vascular 
damage. These include polyols, advanced glycation end 
products and reactive oxygen intermediates [23]. Anatomical 
correlates of the progression of DR include death of capillary 
pericytes, basement membrane thickening, and entrapment of 
leukocytes, leading to capillary blockages and local hypoxia 
[23]. Upregulation of VEGF is likely to occur either directly, 
through stimulation by metabolites such as advanced glycation 
end products  and reactive oxygen intermediates, or indirectly, 
through the local hypoxia induced by capillary dropout. VEGF is 
synthesized by a wide range of retinal cell types and this 
synthesis is significantly increased in hypoxic conditions. 
Clinical findings have confirmed that VEGF levels are elevated 
in both DR and DME [25]. It is now well established that 
increases in  ocular concentrations of VEGF are closely linked 
both to the aberrant growth of new vessels and to increased 
exudation and tissue edema. This edema further exacerbates 
the vision loss associated with DR (see Callout 3) and other 
ocular neovascularizing syndromes such as age-related 
macular degeneration (AMD). 
The neovascularization and edema signal two of VEGF’s salient 
properties: (1) as a central promoter of angiogenesis and (2) as 
the most potent known enhance of vascular permeability. The 
increase in permeability reflects several VEGF-mediated 
processes, including induction of fenestrations in the 
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endothelium [64], dissolution of tight junctions [10], and of 
promotion adherence to the retinal vasculature by leukocytes 
which then act to damage the endothelium. 
 
Fig. 4  Retinal vascular endothelial growth factor mRNA levels are increased in early diabetes. 
(Adapted from [63]) 
 
 
 
Pegaptanib 
 
Pegaptanib is a nuclease-resistant, pegylated 28-nucleotide 
RNA aptamer (Fig. 5 ) that binds to the VEGF164/165 isoform 
at high affinity (200 pM) while showing little activity toward 
the VEGF120/121 isoform  (see Callout 4). Pegaptanib inhibits 
VEGF164/165 from binding to its cellular receptors, 
preventing the initiation of downstream signaling events. From 
the perspective of DR and DME, two of the most important 
cellular processes which are inhibited are VEGF’s actions in 
promoting angiogenesis and in enhancing vascular 
permeability. In experiments with cultured endothelial cells, 
pegaptanib inhibited the induction of mitogenesis by VEGF165, 
but not by VEGF121, consistent with pegaptanib’s specificity 
for VEGF165 [26]. In addition, in the Miles assay for vascular 
permeability, the VEGF-induced increase in vascular leakage 
was inhibited by 83% when VEGF was pre-incubated with 
pegaptanib. In subsequent studies, using a rodentmodel of 
retinopathy of prematurity, intravitreous injection of 
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pegaptanib was shown to inhibit pathological 
revascularization, but not the physiological vascularization of 
the retina, suggesting that pegaptanib treatment might 
be relatively harmless to the normal retinal vasculature. 
Further evidence of pegaptanib’s sparing of physiological 
tissues came from studies of retinal ischemia in which 
VEGF120 was shown to be sufficient to exert a neuroprotective 
effect. Most importantly for DR, in experiments with diabetic 
rodents, intravitreous injection of pegaptanib was shown to 
cause restoration of the BRB (Fig. 6 ). 
Pegaptanib includes a 40-kDa polyethylene glycol moiety at the 
5’ terminal, a change that prolongs intravitreal half-life. 
Pivotal phase 3 trials [27] have already demonstrated that 
intravitreously adaministered pegaptanib is effective in 
treating neovascular AMD and is associated with a low risk of 
adverse events such as endophthalmitis, traumatic lens injury 
or retinal detachment; where these occurred they were related 
to the injection procedure rather than to the study drug itself. 
The success of the trials led to pegaptanib’s approval for 
neovascular AMD by regulatory authorities in the United 
States, Canada and Brazil, and its recommendation for market 
authorization by the Committee for Human Medicinal Products 
of the European Union. 
Taken together with the data implicating VEGF165 in the 
pathophysiology of DR/DME, and the positive safety record of 
pegaptanib in clinical trials, these findings led to a phase 2 trial 
to examine pegaptanib’s utility as a treatment for DME. 
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Fig. 5  Pegaptanib – secondary structure. PEG polyethylene glycol (With permission from [56]) 
 
 
 
 
 
 
Fig. 6  Suppression of diabetic blood-retinal barrier (BRB) breakdown by antivascular endothelial 
growth factor 165 aptamer.Compared with polyethylene glycol (PEG) alone, treatment with pegaptanib 
resulted in a 82.6% blockade of early diabetic BRB breakdown (P<0.01) and b 55.0% blockade of 
established diabetic BRB breakdown (P<0.01). (Adapted from [35], with permission) 
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Phase 2 Trial –  
Intravitreous Pegaptanib as a Treatment for DME 
19.3.2.2.1 Design 
The study was a randomized, sham-controlled, double-masked, 
dose-finding phase 2 trial which enrolled 172 patients 18 years 
and older with type I or type II diabetes, visual acuity (VA) 
between 20/50 and 20/320 and clinically significant DME 
affecting  the center of the macula (see Callout 5). Only 
patients judged not likely to need photocoagulation therapy for 
16 weeks were enrolled. Principal exclusion criteria included 
photocoagulation or other retinal treatments within the 
previous 6 months, abnormalities preventing VA or 
photographic measurements, severe cardiac disease, clinically 
significant peripheral vascular disease, uncontrolled 
hypertension, and glycosylated hemoglobin levels 13% [28]. 
Patients were randomized to four treatment arms (0.3 mg, 1 
mg or 3 mg pegaptanib or sham injection), with stratification 
by study site, size of the thickened retina area ( 2.5 disk areas 
versus >2.5 disk areas), and baseline VA (letter score 58 versus 
<58). Injections were given at baseline and every 6 weeks 
thereafter for a minimum of three and a maximum of six 
injections. Final assessments were made at week 36, or 6 
weeks after the last injection. Refraction, VA assessment, an 
ophthalmologic examination, optical coherence tomography 
(OCT), and color fundus photography were conducted at 
baseline and at each visit, while fluorescein angiography was 
carried out at baseline and  6 weeks after the last injection. 
Overall, 169 patients  received at least one injection, and more 
than 90% of patients in each treatment group completed the 
study. Prespecified efficacy criteria included VA, retinal 
thickness as measured by OCT, and the need for rescue 
photocoagulation therapy. In addition, patients found to show 
diabetic neovascularization at baseline were evaluated for the 
impact of pegaptanib treatment upon its advance or regression. 
 
19.3.2.2.2 Results 
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Principal Endpoints –  
Visual Acuity, Retinal Thickness, Retinal Volume, 
and Need for Photocoagulation. 
 
Pegaptanib treatment was superior to sham injection according 
to all prespecified endpoints.Mean change in VA in the 0.3 mg 
pegaptanib-treated group was +4.7 letters compared to –0.4 
letters for sham (P=0.04; Table 9). Pegaptanib treatment also 
resulted in more patients gaining 0, 5, 10, and 15 letters of VA 
(Fig. 6). Mean change in center point retinal thickness was –68 
μm in the 0.3 mg pegaptanib arm compared to +3.7 μm in the 
sham group (P=0.02), and pegaptanib treatment resulted in 
significantly more patients experiencing decreases in thickness 
of 75 and 100 μm (Table 10). As well, macular volume 
decreased 58mm3 in the 0.3 mg pegaptanib arm but increased 
12mm3 with sham (P=0.009) [data on file: (OSI) Eyetech, Inc. 
and Pfizer Inc. 2005]. OCT center point thickness at baseline 
and change in thickness from baseline to week 36 had a modest 
correlation with VA at baseline or change in VA from baseline 
to week 36 (R2=0.18). 
Lastly, in the 0.3 mg pegaptanib arm, only 25% of patients 
required further treatment with photocoagulation, compared 
to 48% in the sham group (P=0.042; Table 9, 10) [29]. 
 
 
Fig. 7  Percentage of patients treated with pegaptanib sodium maintaining or gaining visual acuity 
from baseline to week 36 (intention-to-treat population, N=172). *P<0.05, †P<0.01. (With permission 
from [21]) 
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Ranibizumab for the Treatment of Diabetic Macular Edema 
 
Introduction 
Diabetic retinopathy is the most prevalent cause of vision loss 
among working age adults, and diabetic macular edema (DME) 
is the most common cause of moderate vision loss in 
individuals with diabetes mellitus [9]. Although vision loss with 
DME is frequent, effective treatment with laser 
photocoagulation, metabolic control, intraocular steroids, and 
novel pharmacological therapy such as vascular endothelial 
growth (VEGF) factor blockers may help to decrease DME and 
may reverse vision loss associated with this disease. This 
chapter reviews the pathogenesis of DME, the rationale for the 
role of anti- VEGF agents, and preliminary clinical studies on 
the use of ranibizumab (Lucentis, Genentech Inc., South San 
Francisco, CA) for DME. 
19.3.3.2 Pathogenesis 
Diabetic macular edema occurs fromleakage of plasma into the 
central retina, resulting in thickening of the retina because of 
excess interstitial fluid. The excess interstitial fluid within the 
macula results in stretching and distortion of photoreceptors, 
which eventually leads to decreased vision.Histopathologic 
studies have demonstrated that microaneurysms are likely 
responsible for focal leakage that may be seen in eyes with 
DME. Microaneurysms are thought to form because of 
hyperglycemia-induced pericyte death, which weakens the 
walls of retinal vessels resulting in the formation of small 
aneurysms which lose their barrier qualities and leak [12]. In 
addition to focal leakage caused by microaneurysms, eyes with 
DME may also demonstrate diffuse leakage from retinal 
capillaries that do not show visible structural changes such as 
microaneurysms. This pattern of diffuse leakage may be due 
tomicroscopic damage to retinal vessels that are not visible in 
images obtained during fluorescein angiography. It is possible 
that diffuse leakage results from the presence of excessive 
amounts of permeability factors. 19.3.3.3 Vascular 
Endothelial Growth 
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Factor 
Retinal hypoxia has been implicated in the pathogenesis of 
DME [13]. Hypoxia causes increased expression of VEGF, a 
potent inducer of vascular permeability that has been shown to 
cause leakage from retinal vessels [4, 16]. 
TheVEGF family,which includes VEGF-A,VEGFB, VEGF-C, VEGF-
D, and placental growth factor, plays an important role in 
angiogenesis and vascular permeability [11, 15, 19]. Studies 
have demonstrated that VEGF-A is a primary activator of 
angiogenesis and vascular permeability, whereas other VEGF 
family members play a lesser role in angiogenesis. Nine VEGF-A 
isoforms are produced through alternate splicing of the mRNA 
of the human VEGF-A gene: VEGF121, VEGF145, VEGF148, 
VEGF162, VEGF165, VEGF165b, VEGF183, VEGF189, and 
VEGF206 [20]. 
Among the nine isoforms, VEGF165 is themost abundantly 
expressedVEGF-A isoform, and it plays a critical role in 
angiogenesis. However, other isoforms, such as VEGF121, 
VEGF183, and VEGF189, are also commonly expressed in 
various tissues [8]. Animal studies have demonstrated that 
VEGF-A plays a vital role in the pathogenesis of ocular diseases 
in which neovascularization and increasedvascular 
permeability occur, such as proliferative  diabetic 
retinopathies, macular edema, and neovascular age-related 
macular degeneration (AMD) [1, 5, 6]. Overexpression of VEGF-
A has been reported to cause ocular neovascularization and 
macular edema in monkeys [10]. In addition, elevated levels of 
VEGF-A have been identified in the vitreous of patients with 
diabetic retinopathy [2], and higher VEGF-A levels are found in 
the vitreous and aqueous humor of patients with diabetic 
macular edema.  
Evidence from animal and clinical studies has clearly 
demonstrated a pathologic role for overexpression of VEGF; 
therefore anti-VEGF therapies are likely to have an important 
role in the treatment of DME and proliferative diabetic 
retinopathy. 
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Ranibizumab 
19.3.3.4.1 Biology 
Ranibizumab is an FDA-approved humanized antigen-binding 
fragment (Fab) designed to bind and inhibit all VEGF-A 
isoforms and their biologically active degradation products. 
The vitreous half-life of ranibizumab after intravitreal 
administration in monkeys is 3 days with very low systemic 
exposure following intravitreal administration in both 
humans and monkeys [ 30 ]. 
19.3.3.4.2 Clinical Experience in Age-Related 
Macular Degeneration 
Phase I/II/III clinical trials in patients with choroidal 
neovascularization (CNV) secondary to AMD have hown 
intravitreal injection of ranibizumab to be safe and well 
tolerated. In addition, two pivotal phase III clinical trials 
[Minimally-Classic/Occult Trial of the Anti-VEGF Antibody 
Ranibizumab In the Treatment of Neovascular AMD(MARINA) 
Trial and the Anti-VEGF Antibody for the Treatment of 
Predominantly Classic Choroidal Neovascularization in AMD 
(ANCHOR) Trial] demonstrated the efficacy of ranibizumab in 
patients with neovascular AMD; these studies were the first to 
show visual improvement, not just a stabilization of visual 
acuity, in individuals with neovascular AMD. 
 
The MARINA Trial was a randomized, doublemasked, sham-
controlled clinical trial of patients with minimally classic or 
occult with no classic CNV secondary to AMD who were treated 
with monthly intravitreal ranibizumab (0.3 or 0.5 mg) or sham 
injections for 24 months. In the MARINA trial,  approximately 
90–92% of ranibizumab-treated patients lost fewer than 15 
letters of VA compared with 53% of sham-injected patients 
after 24 months [31]. In addition, at 24 months of follow-up, 
approximately 33% of ranibizumab-treated patients 
experienced visual improvement of 15 ormore letters 
compared with 4% of the sham-injected patients. 
The ANCHOR Trial was a randomized, doublemasked, sham-
controlled clinical trial of patients with predominantly classic 
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CNV secondary to AMD treated with intravitreal ranibizumab 
(0.3 or 0.5 mg) and sham photodynamic therapy (PDT) or sham 
injection and PDT (monthly administration for ranibizumab 
and every 3 months for PDT) for 24 months. After 12 months of 
follow-up, 94% and 96% of ranibizumabtreated patients (0.3 
and 0.5 mg, respectively) lost fewer than 15 letters of VA 
compared with 64% of PDTtreated atients [32]. In addition, 
36%and 40%of ranibizumab-treated patients experienced 
visual improvement of 15 or more letters (0.3 and 0.5 mg, 
respectively) compared with 6% of PDT-treated patients. 
 
Ranibizumab in Diabetic Macular  Edema 
 
 
Nguyen and colleagues conducted an open-label study 
(Ranibizumab for Edema of themAcula in Diabetes: A Phase I 
Study – the READ-1 Study) to investigate the effect of 
intravitreal injections of ranibizumab in 20 patients with DME 
[33]. Intraocular injections of 0.5 mg of ranibizumab were 
administered at study entry and at 1, 2, 4, and 6 months after 
entry. The injection regimen was selected to assess the effect of 
3monthly injections and then determine the impact of 
increasing the time interval between injections to 2 months for 
the last two injections. The primary outcome measure was 
foveal thickness measured by optical coherence tomography 
(OCT) at 7 months compared to baseline. Secondary outcome 
measures were macular volume measured by OCT and visual 
acuity measured by the protocol of the Early Treatment 
Diabetic Retinopathy Study (ETDRS) [34] at 7 months 
compared to baseline. Among the first ten subjects (five men 
and five women) enrolled, pertinent baseline characteristics 
included  eight eyes that had received at least two sessions of 
focal/grid laser photocoagulation not less than 5 months prior 
to study entry (range 5–120months), three eyes that had 
received intraocular steroids not less than 10 months prior to 
entry (range 10–20 months), and a mean foveal thickness 
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of 503•}115 μm (range 326–729 μm) at baseline, indicating 
the presence of severe, chronic DME that was poorly 
responsive to standard therapies. 
 
Effect on Foveal Thickness and Macular Volume 
 
 
OCT scans from two subjects whose DME showed response to 
ranibizumab are shown in Fig. 8. Compared to baseline, mean 
foveal thickness was reduced by 246 μm at the primary 
endpoint of the study (7 months after the first ranibizumab 
injection), representing an elimination of 85% of the excess 
foveal thickness that had been present at baseline. OCT scans 
from two subjects are shown in Fig. 8 . In addition, mean 
macular volume was reduced from 9.22mm3 at baseline to 
7.47mm3 at 7months, a reduction of 1.75 mm3 which was 
statistically significant (P=0.009). This reduction constituted 
77% of the excessmacular volume that was present at baseline. 
19.3.3.5.2 Effect on Visual Acuity 
Throughout each study time point, mean and median visual 
acuities were better than those at baseline. At the primary 
endpoint (7 months after the initial ranibizumab injection), 
mean and median visual acuity improved by 12.3 and 11 
letters, which represents an improvement of a little more than 
2 lines (Fig. 9). 
In this study cohort, there was a strong correlation (R2 value of 
0.78) between visual acuity and foveal thickness as measured 
by OCT (Fig. 10). However, the rate of change of these two 
outcome measures was different, and rapid changes in foveal 
thickness were associated with more gradual improvements in 
visual acuity.  
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Fig. 8 
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Fig. 8 - 9 - 10 
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Further studies are underway to investigate the correlation 
between visual acuity and retinal thickness as measured by 
OCT. 
19.3.3.5.3 Safety 
Intraocular injections of ranibizumab were tolerated well with 
no ocular inflammation or adverse events. There were no 
systemic adverse events, thromboembolic events, cerebral 
vascular accidents, or myocardial infarctions. Capillary 
nonperfusion was measured by image analysis at baseline and 
month 6 fluorescein angiograms with the investigator masked 
with respect to time point. The mean area of nonperfusion was 
0.19812 disk areas at baseline and 0.19525 at 6months. 
Therefore, no significant change in capillary nonperfusion was 
seen throughout the study. 
19.3.3.6 Summary 
Treatment of DME is complex and involves both systemic and 
ocular therapies. Although focal laser photocoagulation is 
considered the gold standard for the treatment of macular 
edema, novel therapies directed at decreasing vascular 
permeability at the molecular level with anti-VEGF agents have 
shown beneficial effects in early clinical trials. The READ-1 
Study has demonstrated safety, tolerability, and bioactivity of 
intravitreal ranibizumab in subjects with DME. A large, 
multicenter, phase II trial, the READ-2 Study, is underway: (a) 
to obtain data on the bioactivity and dose interval effects of 
intravitreal ranibizumab alone, as well as in combination with 
laser photocoagulation, on retinal thickness and visual acuity in 
subjects with DME; and (b) to obtain additional safety and 
bioactivity data to aid in the design of a phase III clinical trial 
to evaluate ranibizumab as a therapeutic option for patients 
with DME. Novel anti-VEGF agents such as ranibizumab may 
provide additional therapeutic options to the 
armamentariumof treatments for DME. 
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